P&G, Sanofi win U.S. approval for new Actonel dose

NEW YORK, April 17 (Reuters) - U.S. regulators approved a dose of the osteoporosis drug Actonel that will allow patients to take one tablet on two consecutive days, for a total of two tablets monthly, the drug's marketers Procter & Gamble PG.N and Sanofi-Aventis SASY.PA said on Tuesday.

The new dose of Actonel, 75 milligrams, will soon be available in this monthly two-day dose option, the companies said.

((Reporting by Lewis Krauskopf, editing by Martin Golan; Reuters Messaging:;; 646-223-6082)) Keywords: PROCTER SANOFI/ACTONEL

C Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWEN6513